Adaptimmune

John Lunger, Chief Patient Supply Officer

Philadelphia, PA

(NASDAQ: ADAP)

Virtual Presentation

Adaptimmune, a leader in T cell therapy, has clinical trials ongoing for three wholly owned SPEAR T cells in multiple solid tumor indications. The company’s unique SPEAR T cell platform enables the engineering of T cells to target and destroy cancer, including solid tumors. We have generated a strong pipeline of affinity-enhanced T cell therapies, with multiple INDs open. We use these therapies to harness the body’s own immune system to find and destroy diseased cells. Our SPEAR T cell therapies offer promise to patients that often have no other options. We are working hard to make that promise a reality. Adaptimmune partners with industry leaders in all areas of its business.

www.adaptimmune.com



By using this website you agree to accept our Privacy Policy and Terms & Conditions